I hereby certify that this correspondence is being deposited with the United States Postal Service as

first class mail in an envelope addressed to:

Commissioner for Patents, Mail Stop DD, P.O. Box 1450,

Alexandria, VA 22313 on December 16.

David R. Saliwanchik, Patent Attorney

INFORMATION DISCLOSURE **STATEMENT** Examining Group 1646 Patent Application Docket No. GJE-6089D2 Serial No. 10/658,219

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Art Unit

1

1646

Applicant

Bruce Joseph Roser

Serial No.

10/658,219

Filed

September 8, 2003

For

Dried Blood Factor Composition Comprising Trehalose

Mail Stop DD Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §§1.97 AND 1.98

Sir:

In accordance with 37 CFR §1.56, the references listed on the attached form PTO/SB/08 are being brought to the attention of the Examiner for consideration in connection with the examination of the above-identified patent application. A copy of each cited reference is enclosed.

The applicant respectfully asserts that the substantive provisions of 37 CFR §§1.97 and 1.98 are met by the foregoing statement.

Respectfully submitted,

David R. Saliwanchik

Patent Attorney

Registration No. 31,794

Phone No.:

352-375-8100

Fax No.:

352-372-5800

Address:

2421 N.W. 41st Street, Suite A-1

Gainesville, FL 32606-6669

DRS/la

Attachments: Form PTO/SB/08; copies of references cited therein.



PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)					Application Number	10/658,219
					Filing Date	September 8, 2003
					First Named Inventor	Bruce Joseph Roser
					Art Unit	1646
					Examiner Name	Not yet assigned
	Sheet	11	of	2	Attorney Docket Number	GJE-6089D2

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. 1	Document Number Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
	U1	US-4,495,175 A	Chavin et al.	1-22-1985		
	U2	US-4,758,657 A	Farb et al.	7-19-1988		
	U3	US-4,806,343 A	Carpenter et al	2-21-1989		
	U4	US-4,891,319 A	Roser	01-02-1990	-	
	U5	US-5,364,756 A	Livesey et al.	11-15-1994		
_	U6	US-5,576,291	Curtis	11-19-1996		
	U7	US-6,649,386 B2	Roser	11-18-2003		
	U8	US-				
_	U9	US-				

FOREIGN PATENT DOCUMENTS						
	Cite No. ¹	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
Examiner Initials*		Country Code 3 - Number 4 - Kind Code5 (if known)	Publication Date MM-DD-YYYY			T ⁶
	F1	EP 0 314 095 A1 3	05-03-1989	Rorer International (Overseas) Inc.		
	F2	EP 0 475 409 A2 >	03-18-1992	Lifecell Corporation		
	F3	WO 87/00196	01-15-1987	Quadrant Bioresources Limited		
	F4	WO 94/07510 A1 >	04-14-1994	Kabi Pharmacia AB		
	F5	WO 95/01804 ♀	01-19-1995	Kabi Pharmacia AB		
	F6	WO 95/07713 ✓	03-23-1995	Baxter International		
	F7					

[Examiner	Date
Signature	Considered

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (08-03) Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

C mplete if Known Substitute for form 1449B/PTO **Application Number** 10/658.219 INFORMATION DISCLOSURE **Filing Date** September 8, 2003 STATEMENT BY APPLICANT **First Named Inventor** Bruce Joseph Roser **Group Art Unit** 1646 (use as many sheets as necessary) **Examiner Name** Not yet assigned Sheet **Attorney Docket Number** of GJE-6089D2

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²		
	R1	Cleland, J.L. et al. (ed) "Design and Development Strategies" Chapter 1 in Formulation and Delivery of Proteins and Peptides, American Chemical Society Symposium Series (1994) 567:1-19.			
•	R2	Roser, B. et al. "Trehalose Drying: A Novel Replacement for Freeze-Drying" BioPharm (September 1991) vol. 4(8):47-53.			
	R3				
	R4				
	R5				
	R6				
	R7				
	R8				
	R9				
	R10				
	R11	·			
	R12		<u> </u>		
	R13				

Examiner	Date
Signature	Considered Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance

and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional).

Applicant's unique citation designation number (optional).

Applicant's unique citation designation number (optional).

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO). to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.